Ethinylestradiol/desogestrel - Teva

Drug Profile

Ethinylestradiol/desogestrel - Teva

Alternative Names: DR-102; DR-1021; LeCette

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Alkylated estrogenic steroids; Hormonal contraceptives; Norpregnatrienes; Norpregnenes; Oral contraceptives
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Contraception

Most Recent Events

  • 02 Feb 2014 Teva Pharmaceutical Industries has patent protection for ethinylestradiol/desogestrel in USA
  • 30 Sep 2013 Preregistration for Contraception/Pregnancy (Prevention) in USA (PO)
  • 08 May 2013 Efficacy and adverse events data from a phase I trial in Contraception/Pregnancy (Prevention) released by Teva Pharmaceutical Industries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top